Novozymes (NZYM-B.CO) Stock Analysis & AI Equity Report
Novozymes (NZYM-B.CO) overview
Novozymes (NZYM-B.CO) stock analysis and AI equity research. For the latest completed financial year, 2024, Novozymes reported revenue of EUR 3,834m and operating profit of EUR 659m; the year-end share price was N/A and market capitalisation was N/A. Novozymes is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Novozymes's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-01. Data will be refreshed during report generation.
About Novozymes
Novozymes A/S develops enzyme- and microbe-based biosolutions used across food and beverages, human health, household care, agriculture, energy and other industrial applications. Its products help customers improve process efficiency, product performance and resource use. The company was combined with Chr. Hansen in 2024 to form Novonesis, reflecting a broader biosolutions platform.
Generate the Novozymes report
Novozymes is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Novozymes and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.